Brief: LifeMd To Offer Market-Leading Pricing For Glp-1 Medications Wegovy And Ozempic In Continued Collaboration With Novo Nordisk
17/11/2025 13:02
Nov 17 (Reuters) - LifeMD Inc LFMD.O: LIFEMD® TO OFFER MARKET-LEADING PRICING FOR GLP-1 MEDICATIONS WEGOVY® AND OZEMPIC® IN CONTINUED COLLABORATION WITH NOVO NORDISK LIFEMD INC - OFFERS GLP-1 MEDICATIONS AT $199 PER MONTH Source text: ID:nGNXbdRrtY Further company coverage: LFMD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on LifeMD
See all newsLifeMD Q1 revenue beats estimates on record telehealth subscriber additons
Brief: LifeMD Q1 Adjusted EBITDA USD -4.5 Million Vs. IBES Estimate USD -4.66 Million
LifeMD rises after adding new daily obesity pill to weight management program
Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US (updated)
Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US